WMG
CRL icon

WESCAP Management Group’s Charles River Laboratories CRL Stock Holding History

WESCAP Management Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$360K Hold
2,085
– – 0.07% 98
2025
Q4 		$416K Sell
2,085
-358
-15% -$64.9K 0.08% 94
2025
Q3 		$382K Hold
2,443
– – 0.08% 89
2025
Q2 		$371K Buy
2,443
+89
+4% +$11.9K 0.08% 86
2025
Q1 		$354K Sell
2,354
-44
-2% -$7.38K 0.09% 86
2024
Q4 		$443K Buy
2,398
+46
+2% +$8.86K 0.11% 80
2024
Q3 		$463K Buy
2,352
+168
+8% +$34.9K 0.12% 71
2024
Q2 		$451K Hold
2,184
– – 0.13% 74
2024
Q1 		$592K Sell
2,184
-17
-0.8% -$4.06K 0.17% 66
2023
Q4 		$520K Sell
2,201
-413
-16% -$81.2K 0.17% 66
2023
Q3 		$512K Sell
2,614
-125
-5% -$25.7K 0.18% 65
2023
Q2 		$576K Buy
2,739
+153
+6% +$30.4K 0.2% 64
2023
Q1 		$522K Sell
2,586
-188
-7% -$42.6K 0.18% 70
2022
Q4 		$604K Sell
2,774
-77
-3% -$16.8K 0.21% 63
2022
Q3 		$561K Sell
2,851
-26
-0.9% -$5.61K 0.21% 68
2022
Q2 		$615K Sell
2,877
-54
-2% -$13.2K 0.21% 68
2022
Q1 		$832K Hold
2,931
– – 0.24% 64
2021
Q4 		$1.1M Sell
2,931
-273
-9% -$106K 0.3% 56
2021
Q3 		$1.32M Sell
3,204
-78
-2% -$32.4K 0.38% 49
2021
Q2 		$1.21M Sell
3,282
-265
-7% -$88.5K 0.35% 50
2021
Q1 		$1.03M Sell
3,547
-95
-3% -$26.4K 0.28% 53
2020
Q4 		$909K Sell
3,642
-357
-9% -$85K 0.27% 54
2020
Q3 		$905K Sell
3,999
-247
-6% -$51.3K 0.3% 51
2020
Q2 		$740K Sell
4,246
-276
-6% -$44K 0.26% 56
2020
Q1 		$570K Hold
4,522
– – 0.24% 61
2019
Q4 		$690K Sell
4,522
-170
-4% -$23.5K 0.27% 51
2019
Q3 		$621K Sell
4,692
-242
-5% -$32.4K 0.26% 52
2019
Q2 		$700K Hold
4,934
– – 0.29% 54
2019
Q1 		$716K Sell
4,934
-185
-4% -$24.3K 0.31% 52
2018
Q4 		$579K Hold
5,119
– – 0.28% 54
2018
Q3 		$688K Sell
5,119
-1,610
-24% -$199K 0.35% 48
2018
Q2 		$755K Sell
6,729
-960
-12% -$104K 0.36% 49
2018
Q1 		$820K Sell
7,689
-8,540
-53% -$921K 0.33% 52
2017
Q4 		$1.78M Sell
16,229
-226
-1% -$24.6K 0.7% 37
2017
Q3 		$1.78M Sell
16,455
-1,157
-7% -$119K 0.8% 33
2017
Q2 		$1.78M Sell
17,612
-260
-1% -$23.9K 0.84% 30
2017
Q1 		$1.61M Buy
17,872
+835
+5% +$70.9K 0.78% 32
2016
Q4 		$1.3M Sell
17,037
-296
-2% -$22.5K 0.66% 34
2016
Q3 		$1.45M Sell
17,333
-370
-2% -$31K 0.75% 30
2016
Q2 		$1.46M Buy
+17,703
New +$1.46M 0.72% 32

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WESCAP Management Group's CRL Position: Q1 2026 in Review

WESCAP Management Group held its Charles River Laboratories (CRL) position steady in Q1 2026 at 2,085 shares worth $360K. The position accounts for 0.07% of the portfolio, ranked #98.

WESCAP Management Group first reported a position in CRL in Q2 2016 and has held it in 40 quarters since. The position peaked at $1.78M in Q2 2017. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • WESCAP Management Group held 2,085 shares of Charles River Laboratories worth $360K as of Q1 2026.
  • WESCAP Management Group left its Charles River Laboratories share count unchanged in Q1 2026.
  • Charles River Laboratories made up 0.07% of WESCAP Management Group's portfolio in Q1 2026, its #98 holding.
  • WESCAP Management Group first reported a position in Charles River Laboratories in Q2 2016 and has held it in 40 quarters since.
  • WESCAP Management Group's Charles River Laboratories position peaked at $1.78M in Q2 2017.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on WESCAP Management Group's 13F filing for Q1 2026, filed 12 May 2026.